Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer | Zendy

June M. Chan | Zendy; William Oh | Zendy; Wanling Xie | Zendy; Meredith M. Regan | Zendy; Meir J. Stampfer | Zendy; Irena B. King | Zendy; Miyako Abe | Zendy; Philip W. Kantoff | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer

Author(s) -

June M. Chan,

William Oh,

Wanling Xie,

Meredith M. Regan,

Meir J. Stampfer,

Irena B. King,

Miyako Abe,

Philip W. Kantoff

Publication year - 2009

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2008.18.8938

Subject(s) - prostate cancer , medicine , sod2 , selenium , oncology , cancer , relative risk , gastroenterology , superoxide dismutase , oxidative stress , confidence interval , chemistry , organic chemistry

In vitro, in vivo, and epidemiologic studies support a role for selenium in reducing the risk of prostate cancer. Our group previously demonstrated a strong interaction between plasma selenium and the manganese superoxide dismutase (SOD2) gene and incident prostate cancer risk. We now hypothesized that SOD2 modifies the association between selenium level and risk of aggressive prostate cancer at diagnosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research